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Introduction
Epilepsy is a clinically and genetically heterogeneous group of disorders. Mutations in 
genes encoding ion channels in brain neurons have been identified in various epilepsy 
syndromes. The advent of molecular genetics brings unprecedented advancement in 
terms of diagnostic molecular pathology and reduces over-reliance on traditional clinical 
classification. An accurate genetic diagnosis enables personalised medicine in this 
heterogeneous group of disorders. Severe myoclonic epilepsy of infancy (SMEI) or Dravet 
syndrome (MIM #607208) is a catastrophic infantile-onset epilepsy affecting about 1 in 
20 000 to 40 000 children with a two-fold preponderance in males.1,2 After a period of normal 
development, affected infants develop febrile and afebrile generalised tonic-clonic (GTC) 
with onset usually within 1 year of age. Some progress into multiple seizure types such 
as focal, absence, and myoclonus. The course may run relentlessly with psychomotor 
retardation, ataxia, recurrent status epilepticus and death. Up to half of the patients have 
a positive family history of febrile seizures and epilepsy. Electroencephalography (EEG) 
findings are not definitive. Genetic testing provides a more decisive diagnosis and is 
crucial in guiding the anti-epileptic drugs selection and genetic counselling.
 Severe myoclonic epilepsy of infancy shows loci heterogeneity with at least SCN1A, 
SCN2A, SCN9A and GABRG2 as the culprit genes.3,4 Depienne et al5 conducted the largest 
genotyping study in 333 Dravet patients with 73% harbouring mutations in SCN1A. To 
date, there were 595 mutations reported with 59% missense/nonsense mutations, 9% 
splicing, 23% small insertions/deletions/indels, and 8% gross insertions/deletions/complex 
rearrangements (Human Gene Mutation Database, Professional 2010.2 accessed on 23 
August 2010). However, most mutations were characterised without functional studies, 
as in practice most laboratories cannot undertake such assessments. Their pathogenicity 
is commonly documented by disease phenotype cosegregation, conservative nature of 
the affected amino acid among different species as well as the absence of the variants 
from screening of ethnically matched normal subjects. Therefore, reporting various 
phenotype-genotype data from more SMEI patients can increase the level of confidence 
about what is suspected. On the other hand, genotypic data in Chinese are limited.6,7 We 
report the first two cases of SMEI molecular analysis in two unrelated Hong Kong Chinese 
patients.
Case reports
Case 1 
A 9-year-old boy first presented at the age of 5 months with a GTC for 20 minutes during 
an episode of fever in September 2002. Within the next 24 hours, he had an atypical febrile 
convulsion with another generalised seizure lasting 7 minutes. The seizure was aborted 
with rectal diazepam. General investigations including EEG, brain computed tomography 
(CT) and magnetic resonance imaging (MRI), cerebrospinal fluid (CSF) culture, protein 
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Epilepsy is a clinically and genetically heterogeneous group of disorders. The advent of 
molecular genetics brings unprecedented advancement in diagnostic molecular pathology 
and reduces over-reliance on traditional clinical classification. Severe myoclonic epilepsy of 
infancy or Dravet syndrome is a catastrophic infantile-onset epilepsy. We report two unrelated 
Hong Kong Chinese patients with this condition presenting with febrile seizures, epilepsy 
with different semiologies, psychomotor retardation, and recurrent status epilepticus. Two 
different mutations were characterised, viz NM_001165963.1: c.680T>G; NP_001159435.1: 
p.I227S and NM_001165963.1: c.3953T>G; NP_001159435.1: p.L1318R (novel). Genetic 
characterisation conveys a definitive diagnosis and is important from the perspective of 
selecting anti-epileptic drug therapy and genetic counselling.
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癲癇是一種臨床上與遺傳學上都有廣泛不同表現的疾病。分子遺傳
學的出現為分子病理學帶來前所未有的發展，亦避免對傳統臨床的
分類過份依賴。嬰兒嚴重肌陣性癲癇（又稱Dravet綜合症）於嬰孩
時期開始發病。本文報告分別兩名香港華籍患者，病發時出現高熱
驚厥、不同的癲癇症狀、精神運動發育遲緩，以及復發性癲癇持
續狀態。為病人確認出分別兩種不同的突變：NM_001165963.1: 
c.680T>G；NP_001159435.1:p.I227S及NM_001165963.1: 
c.3953T>G；NP_001159435.1: p.L1318R （新發現）。遺傳學特徵
分析有助確診，並對於選擇抗癲癇藥物治療及遺傳諮詢扮演著很重要
的角色。
因香港華籍嬰兒嚴重肌陣性癲癇（Dravet綜合
症）相關性SCN1A突變的基因診斷
and glucose measurements, all of which yielded 
no abnormality. He was managed as atypical febrile 
convulsion and roseola infantum on discharge. 
However, he continued suffering from repeated 
attacks. Thus, at the age of 8 and 9 months, he had 
afebrile focal seizures starting with right upper 
limb twitching going on to four limbs convulsive 
movements. Before the age of 1 year, he had had 
six convulsions that were usually associated with 
fever and/or infections. An interictal EEG at the age 
of 6 months was normal but the one performed at 
the age of 10 months revealed bifrontal sharp waves, 
especially over right side. The patient enjoyed normal 
development until he was 1 year old. Psychomotor 
retardation was detected from the age of 2 years. 
When assessed at the age of 31 months, his mental 
age was only 9 to 12 months, and his gross motor age 
was 18 months. He suffered from status epilepticus 
when he was 5 years old and subsequently endured 
regression in motor and cognitive function. His 
brain MRI performed at 10 months old was normal, 
but when repeated at the age of 5 years, it showed 
mild cerebral atrophy. He became bed-bound; 
developed limb rigidity, dystonia and later still 
choreoathetoid movements, whilst continuing 
to suffer from frequent (mainly partial) seizures, 
despite treatment with multiple anticonvulsants. His 
current medications included: sodium valproate, 
levetiracetam, topiramate and clobazam. He had no 
family history of epilepsy or febrile convulsions. 
Case 2 
An 18-year-old boy, first presented when aged 2 
months with an afebrile GTC lasting for 45 minutes 
in December 1992. Septic work-up revealed an 
Escherichia coli urinary tract infection. He suffered 
an afebrile focal seizure with left eye blinking and left 
limbs twitching for 45 minutes at the age of 5 months, 
and then five attacks of GTC followed by transient right 
hemiparesis at the age of 6 months. He had frequent 
seizures in various forms (eye blinking, myoclonic, 
focal, and GTC), and were easily provoked by fever, 
infection and sometimes defaecation. There was a 
strong family history of febrile convulsions in three 
paternal aunts and one paternal cousin. The patient 
showed global delay, first noticed when 11 months 
old. Griffiths Mental Development Scales at the age 
of 25 months revealed an overall development to age 
12 to 17 months only. Routine investigations (liver 
and renal function tests, complete blood picture, and 
metabolic screening) were normal. His EEG, brain CT, 
MRI, and MR angiography at the age of 1 year were all 
normal. However, subsequent EEG studies at the age 
of 5 years showed epileptiform discharges on both 
sides and spikes/polyspikes during photic stimulation, 
while the latest EEG at the age of 10 years showed 
bifrontal epileptiform discharges. An interictal 
single-photon emission computed tomography 
(SPECT) scan examination performed when he was 
8 years old revealed slightly reduced tracer uptake 
over right temporal lobe, but subtraction ictal SPECT 
images could not be obtained. Brain MRI when he 
was aged 15 years remained normal. The response to 
treatment with multiple antiepileptics was poor; he 
currently takes topiramate, valproate, and clobazam.
 From both patients, peripheral blood samples 
were collected after obtaining informed consent. 
Genomic DNA was extracted using a QIAamp blood 
kit (Qiagen, Hilden, Germany). All the coding exons 
and the 10-bp flanking regions of the SCN1A gene 
were amplified by polymerase chain reaction and 
direct DNA sequencing. Primer sequence and 
protocols are available upon request. Two different 
mutations were identified—in case 1, NM_001165963.1: 
c.3953T>G; NP_001159435.1: p.L1318R (novel); in case 2, 
NM_001165963.1: c.680T>G; NP_001159435.1: p.I227S. 
The p.L1318 amino acid was conserved among species. 
In silico analysis by SIFT and PolyPhen predicted it to 
be intolerant and possibly damaging, respectively. 
Parents of case 1 did not carry p.L1318R. The other 
mutation was previously reported in another SMEI 
patient (p.I227S).8 Samples from the parents of case 2 
were not available for genetic analysis. 
Discussion
The pathogenesis of non-syndromic epilepsy has 
been excitingly unravelled in recent years. The 
channelopathy involves more than 10 genes encoding 
various neuronal channels and neurotransmitter 
receptors. The SMEI caused by SCN1A, SCN2A, and 
GABRG2 is exemplary. Both the clinical phenotypes 
and genetic aetiologies of SMEI are heterogeneous 
and can be overlapping. Dravet syndrome is 
characterised by multiple seizure types. It can 
manifest as GTC, myoclonic, myoclonic-astatic, or 
absences. The seizures are relatively refractory to 
anti-epileptic treatment, and are usually preceded 
by febrile convulsion at early age in an otherwise 
normal infant. Patients may suffer from subsequent 
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developmental delay and cognitive impairment. 
Hattori et al9 proposed a clinical scoring system for 
screening high-risk patients for genetic testing of 
Dravet syndrome. There are seven clinical predictive 
risk factors, namely onset within the first 7 months of 
life, more than five seizures, hemiconvulsions, focal 
seizures, myoclonic seizures, prolonged seizures, and 
hot water–induced seizures. Our patients had onset 
at 2 and 5 months old respectively, and suffered from 
multiple attacks of refractory seizures with different 
semiologies. The seizures scored more than six marks 
(ie belonged to high-risk groups) and we detected 
SCN1A mutations in both patients. Since the genetic 
analysis of SCN1A is quite laborious, it is useful to 
have a clinical screening score to guide genetic tests.
 Dravet syndrome is inherited as an autosomal 
dominant, so 50% offspring are at risk of the disease. 
In fact, majority of SCN1A mutations are de-novo; 
only about 5% are inherited. Parents of case 1 did not 
carry the p.L1318R mutation according to the DNA 
sequencing results, suggesting a de-novo mutation. 
However, it is noteworthy that parental mosaicism 
has been reported.10-12 Thus, a mutant load in blood 
of less than 15% may not be detected by direct DNA 
sequencing. The possibility of mosaic mutations 
must be addressed for genetic counselling and 
prenatal diagnosis. Proper genetic counselling and 
family screening should be carried out in all at-risk 
subjects.
 A DNA-based diagnosis enables accurate and 
early diagnosis to formulate an optimal management 
plan and can avoid patient suffering from unnecessary 
investigations or treatment. It is common to try 
different anti-epileptic drugs in patients with 
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intractable epilepsy without certain diagnosis. A 
definitive diagnosis offered by molecular genetics 
definitely saves time with respect to drug that should 
be tried and reduces the risks of undesirable choices. 
Early recognition and diagnosis of the SCN1A mutation 
in Dravet syndrome could enhance appropriate 
selection of anticonvulsants. Phenobarbitone, 
valproate, benzodiazepines, zonisamides, bromides, 
stiripentol, topiramate, levetiracetam and ketogenic 
diet are more effective in controlling these types 
of seizure, while treatment with sodium channel 
blockers (phenytoin, carbamazepine, oxcarbazepine, 
lamotrigine) should be avoided.13,14 Both of our 
patients had an increase in seizure attacks on 
lamotrigine. Knowing the exact mutation is helpful 
particularly for the premature stop codon. Ataluren 
(PTC124) is an emerging genetic therapy targeting 
genetic disorders caused by nonsense mutations.15 
Nonsense mutations create premature protein 
truncation. Ataluren is able to induce selective 
ribosomal read-through of the premature stop 
codon, but not the normal stop codon, thus enabling 
a continuing mRNA transcription. Ataluren is now in 
clinical trials mainly for treating patients with cystic 
fibrosis and Duchenne muscular dystrophy. In the 
future, it may be applicable to SMEI patients with 
nonsense mutations. In addition, patients should be 
educated to avoid triggering factors such as hot water 
in hyperthermia-sensitive seizures. 
 In summary, we report the clinical and muta-
tional findings of the two cases of SMEI in Hong Kong 
Chinese and illustrate the importance of molecular 
genetics in the diagnosis and personalised medical 
management of patients with Dravet syndrome. 
